Lipocine (LPCN) shares soared 5.5% in the last trading session to close at $10. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2% gain over the past four weeks.Lipocine’s stock price gain can be attributed to increasing investor confidence in recent pipeline developments of its investigational drug LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The company is evaluating the candidate in phase III stud ...

SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the last patient has completed the final study visit (Last Patient Last Visit) in its Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD). The randomized, double-blind, placebo-controlled study enrolled a total of 90 pa ...

Core Insights - The Drug Safety Monitoring Board (DSMB) has reviewed the ongoing Phase 3 clinical trial of LPCN 1154 and has recommended that the study continue as planned [1] - More than half of the planned participants have completed dosing without any reported dose reductions, discontinuations, drug-related serious adverse events (SAEs), loss of consciousness, or excessive sedation [1] - Topline results are expected to be available in the second quarter of 2026 [1] Company Summary - Lipocine Inc. is a biopharmaceutical company focused on developing innovative products with effective oral delivery using its proprietary technology platform [1] - The ongoing Phase 3 clinical trial is evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of postpartum depression (PPD) [1] - The DSMB review was conducted after approximately one-third of the planned 80 participants (n=30) completed at least the day seven follow-up visit [1]